Cholesterol

Cholesterol

SCHEMBL162271

CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C.O=C(O)C=Cc1ccccc1

nearest known ligand 0.75

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OSBP P22059 4/20 0.75
RORC P51449 4/20 0.75
OSBP2 Q969R2 2/20 0.75
USP2 O75604 1/20 0.75
LMNA P02545 1/20 0.75
ABCB1 P08183 1/20 0.75
CYP46A1 Q9Y6A2 1/20 0.75
NR1H3 Q13133 7/20 0.66
EPHA2 P29317 1/20 0.66
GRIN1 Q05586 3/20 0.65
GRIN2A Q12879 3/20 0.65
NPC1L1 Q9UHC9 2/20 0.65
CRYAB P02511 1/20 0.65
HMGCR P04035 1/20 0.65
ITGB3 P05106 1/20 0.65
ITGAV P06756 1/20 0.65
SREBF2 Q12772 1/20 0.65
POLA1 P09884 1/20 0.62
GRIN2B Q13224 2/20 0.61
DHCR24 Q15392 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cholesterol SCHEMBL21182319 1.00 OSBP (0.75) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL21182320 1.00 OSBP (0.75) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL19583430 0.92 OSBP (0.86) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL19583433 0.92 OSBP (0.86) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL10379192 0.92 OSBP (0.86) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL28412945 0.91 OSBP (0.84) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL5597221 0.91 OSBP (0.75) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL5597223 0.91 OSBP (0.75) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL27833163 0.90 OSBP (0.82) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL27608874 0.90 OSBP (0.91) OSBPRORCOSBP2USP2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116218033-B Application of organic material in preparing color-changeable polymer material 四川大学 2025-03-14 CN claimed
CN-119044072-A Liquid crystal sensor for detecting formaldehyde gas and preparation method thereof 江南大学 2024-11-29 CN claimed
CN-116218033-A Application of organic material in preparing color-changeable polymer material 四川大学 2023-06-06 CN claimed
CN-116206540-A Multi-mode display layer made of up-conversion liquid crystal microcapsules and display application 苏州科技大学 2023-06-02 CN claimed
CN-114908575-A Liquid crystal ultraviolet-resistant finishing agent and application thereof to textiles 江南大学 2022-08-16 CN claimed
CN-113862823-B Bamboo joint-like liquid crystal fiber and preparation method thereof 江南大学 2022-08-09 CN claimed
CN-113186618-B Preparation method of coaxial electrothermal discoloration liquid crystal fiber 江南大学 2022-03-25 CN claimed
CN-114146649-A Epoxy resin liquid crystal microcapsule and preparation method thereof 江苏集萃智能液晶科技有限公司 2022-03-08 CN claimed
CN-113862823-A Bamboo joint-like liquid crystal fiber and preparation method thereof 江南大学 2021-12-31 CN claimed
CN-113072963-A Monochromatic liquid crystal composition, liquid crystal microcapsule, coating and preparation method thereof 江苏集萃智能液晶科技有限公司 2021-07-06 CN claimed
CN-109375306-B Method for manufacturing cholesteric liquid crystal polymer sheet 厦门大学 2020-04-10 CN claimed
EP-2853264-A1 Nanodispersion Sun Pharma Advanced Research Company Limited (IN) 2015-04-01 EP claimed
CN-102675958-A Liquid crystal display ink ZHANGJIAGANG SHUANGLIN INK COATING CO LTD 2012-09-19 CN claimed
US-20060115445-A1 Compositions for treating keratin materials comprising electrophilic monomers and liquid crystal agents L'OREAL S.A. (FR) 2006-06-01 US claimed
EP-1647259-A1 use for treatment of keratinic materials of compositions comprising electrophilic monomers and agents forming liquid crystals L'OREAL (FR) 2006-04-19 EP claimed
US-6328910-B1 FOR IN SITU FORMATION OF AN POLYMERIC CYANOACRYLATE FILM ON MAMMALIAN SKIN WHICH CAN BE USED TO MONITOR THE SURFACE SKIN TEMPERATURE OF MAMMAL MEDLOGIC GLOBAL CORPORATION 2001-12-11 US claimed
JP-63075707-A None JP disclosed
US-20260102283-A1 PUNCTAL IMPLANTS, INSERTION SYSTEMS AND METHODS OF USING THE SAME GLAUKOS CORP (US) 2026-04-16 US disclosed
US-6328910-B1 FOR IN SITU FORMATION OF AN POLYMERIC CYANOACRYLATE FILM ON MAMMALIAN SKIN WHICH CAN BE USED TO MONITOR THE SURFACE SKIN TEMPERATURE OF MAMMAL MEDLOGIC GLOBAL CORPORATION 2001-12-11 US disclosed
JP-S6375707-A PREPARATION OF FILM THICKNESS DISTRIBUTED FILM FUJITSU LTD 1988-04-06 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060115445-A1 Compositions for treating keratin materials comprising electrophilic monomers and liquid crystal agents KRT18, PRKDC, CUTA OSBP 2396/4885RORC 3212/4885OSBP2 2545/4885
US-20260102283-A1 PUNCTAL IMPLANTS, INSERTION SYSTEMS AND METHODS OF USING THE SAME SSTR5, CFTR, STARD10 OSBP 3329/4885RORC 2052/4885OSBP2 3595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.